Trial Profile
Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection in China
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Lamivudine; Lopinavir/ritonavir; Tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Therapeutic Use
- 08 May 2013 New trial record